130 related articles for article (PubMed ID: 3879782)
1. Is the dialysate fluid source of complement activating factors?
Minetti L; Broggi ML; Civati G; Guastoni C; Teatini U
Trans Am Soc Artif Intern Organs; 1985; 31():673-7. PubMed ID: 3879782
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of biocompatibility of hemophane, cellulose diacetate and acrilonitile membranes in hemodialysis].
Germin Petrović D
Acta Med Croatica; 2004; 58(1):31-6. PubMed ID: 15125391
[TBL] [Abstract][Full Text] [Related]
3. Polyacrylonitrile complement activation attenuated by simultaneous ultrafiltration and adsorption.
Röckel A; Hertel J; Perschel WT; Walb D; Fiegel P; Panitz N; Abdelhamid S
Nephrol Dial Transplant; 1987; 2(4):251-3. PubMed ID: 3118267
[TBL] [Abstract][Full Text] [Related]
4. Biocompatibility of hemodialysis membranes: evaluation in an ovine model.
Burhop KE; Johnson RJ; Simpson J; Chenoweth DE; Borgia J
J Lab Clin Med; 1993 Feb; 121(2):276-93. PubMed ID: 8433041
[TBL] [Abstract][Full Text] [Related]
5. Complement activation and hypersensitivity reactions to dialysis membranes.
Hakim RM; Breillatt J; Lazarus JM; Port FK
N Engl J Med; 1984 Oct; 311(14):878-82. PubMed ID: 6332276
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and kinetics of the synthesis and release of platelet-activating factor (PAF) by polyacrylonitrile membranes.
Guastoni C; Tetta C; Hoenich NA; Gervasio R; Sereni L; Tessore E; Wratten ML; Civati G
Clin Nephrol; 1996 Aug; 46(2):132-8. PubMed ID: 8869791
[TBL] [Abstract][Full Text] [Related]
7. Leucopenia, hypoxia and complement activation in haemodialysis. Three unrelated phenomena.
de Vinuesa SG; Resano M; Luño J; Gonzalez C; Barril G; Junco E; Valderrabano F
Proc Eur Dial Transplant Assoc; 1983; 19():159-67. PubMed ID: 6878230
[TBL] [Abstract][Full Text] [Related]
8. Blood-membrane interaction: C3a, an indicator of biocompatibility.
Ivanovich P; Hammerschmidt DE; Chenoweth D; Klinkmann H; Vidovic D
Life Support Syst; 1985; 3 Suppl 1():394-403. PubMed ID: 3879953
[TBL] [Abstract][Full Text] [Related]
9. Different complement and granulocyte activation in patients dialyzed with PMMA dialyzers.
Hörl WH; Riegel W; Schollmeyer P; Rautenberg W; Neumann S
Clin Nephrol; 1986 Jun; 25(6):304-7. PubMed ID: 3015463
[TBL] [Abstract][Full Text] [Related]
10. Mediators of complement-independent granulocyte activation during haemodialysis: role of calcium, prostaglandins and leukotrienes.
Böhler J; Donauer J; Birmelin M; Schollmeyer PJ; Hörl WH
Nephrol Dial Transplant; 1993; 8(12):1359-65. PubMed ID: 8159305
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis.
Arnaout MA; Hakim RM; Todd RF; Dana N; Colten HR
N Engl J Med; 1985 Feb; 312(8):457-62. PubMed ID: 3881672
[TBL] [Abstract][Full Text] [Related]
12. Is platelet-activating factor produced during hemodialysis with AN-69 polyacrylonitrile membrane?
Iatrou C; Afentakis N; Nomikos T; Dinas C; Stavropoulos-Giokas C; Antonopoulou S
Nephron; 2002 May; 91(1):86-93. PubMed ID: 12021524
[TBL] [Abstract][Full Text] [Related]
13. A clinical study on different cellulosic dialysis membranes.
Falkenhagen D; Bosch T; Brown GS; Schmidt B; Holtz M; Baurmeister U; Gurland H; Klinkmann H
Nephrol Dial Transplant; 1987; 2(6):537-45. PubMed ID: 3126455
[TBL] [Abstract][Full Text] [Related]
14. Biocompatibility of dialysis membranes: effects of chronic complement activation.
Hakim RM; Fearon DT; Lazarus JM
Kidney Int; 1984 Aug; 26(2):194-200. PubMed ID: 6334194
[TBL] [Abstract][Full Text] [Related]
15. Role of platelet activating factor in hemodialysis.
Tetta C; David S; Biancone L; Canino F; Cambi V; Camussi G
Kidney Int Suppl; 1993 Jan; 39():S154-7. PubMed ID: 8468919
[TBL] [Abstract][Full Text] [Related]
16. Biocompatibility and performance of a modified cellulosic and a synthetic high flux dialyzer. A randomized crossover comparison between cellulose triacetate and polysulphon.
Grooteman MP; Nubé MJ; van Limbeek J; van Houte AJ; Daha MR; van Geelen JA
ASAIO J; 1995; 41(2):215-20. PubMed ID: 7640431
[TBL] [Abstract][Full Text] [Related]
17. Dialysis leukopenia, hypoxemia, and anaphylatoxin formation: effect of membrane, bath, and citrate anticoagulation.
Wiegmann TB; MacDougall ML; Diederich DA
Am J Kidney Dis; 1988 May; 11(5):418-24. PubMed ID: 3259402
[TBL] [Abstract][Full Text] [Related]
18. Transfer of cytokine-inducing bacterial products across hemodialyzer membranes in the presence of plasma or whole blood.
Pereira BJ; Sundaram S; Barrett TW; Butt NK; Porat R; King AJ; Dinarello CA
Clin Nephrol; 1996 Dec; 46(6):394-401. PubMed ID: 8982556
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo model for pre-clinical evaluation of dialyzers containing new membranes.
Mahiout A; Meinhold H; Jörres A; Krieg R; Kessel M; Tretzel J; Baurmeister U
Life Support Syst; 1985; 3 Suppl 1():448-52. PubMed ID: 3879954
[TBL] [Abstract][Full Text] [Related]
20. Clinical sequelae of complement activation in hemodialysis.
Hakim RM
Clin Nephrol; 1986; 26 Suppl 1():S9-12. PubMed ID: 3829474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
